GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncodesign Precision Medicine SA (XPAR:ALOPM) » Definitions » NonCurrent Deferred Liabilities

Oncodesign Precision Medicine (XPAR:ALOPM) NonCurrent Deferred Liabilities : €0.00 Mil (As of Jun. 2022)


View and export this data going back to 2022. Start your Free Trial

What is Oncodesign Precision Medicine NonCurrent Deferred Liabilities?

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Oncodesign Precision Medicine's non-current deferred liabilities for the quarter that ended in Jun. 2022 was €0.00 Mil.

Oncodesign Precision Medicine NonCurrent Deferred Liabilities Historical Data

The historical data trend for Oncodesign Precision Medicine's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncodesign Precision Medicine NonCurrent Deferred Liabilities Chart

Oncodesign Precision Medicine Annual Data
Trend Dec20 Dec21
NonCurrent Deferred Liabilities
- -

Oncodesign Precision Medicine Semi-Annual Data
Dec20 Dec21 Jun22
NonCurrent Deferred Liabilities - - -

Oncodesign Precision Medicine NonCurrent Deferred Liabilities Related Terms

Thank you for viewing the detailed overview of Oncodesign Precision Medicine's NonCurrent Deferred Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Oncodesign Precision Medicine (XPAR:ALOPM) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
18 rue Jean Mazen, Dijon, FRA, 21000
Oncodesign Precision Medicine SA is a biopharmaceutical company specialised in precision medicine. Its mission is to provide patients with effective diagnostic and therapeutic solutions for resistant and metastatic cancers.

Oncodesign Precision Medicine (XPAR:ALOPM) Headlines

No Headlines